INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243201, 'Glycerol phenylbutyrate', 'Promazine', 'Moderate', 'Coadministration of glycerol phenylbutyrate may lead to increased concentrations of CYP450 2D6 substrates.  The proposed mechanism is inhibition of CYP450 2D6 by phenylbutyrate, the active moiety of glycerol phenylbutyrate, which has been shown to be an in vitro inhibitor of this isoenzyme.', 'DDInter', 'Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate.', 'Metabolism', 'Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279641/', '', 'Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More', 'Thiothixene, Amisulpride, Loxapine, Molindone, Droperidol, Lurasidone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243202, 'Glycerol phenylbutyrate', 'Propiomazine', 'Moderate', 'Coadministration of glycerol phenylbutyrate may lead to increased concentrations of CYP450 2D6 substrates.  The proposed mechanism is inhibition of CYP450 2D6 by phenylbutyrate, the active moiety of glycerol phenylbutyrate, which has been shown to be an in vitro inhibitor of this isoenzyme.', 'DDInter', 'Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate.', 'Metabolism', 'Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279642/', '', 'Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More', 'Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243203, 'Glycerol phenylbutyrate', 'Relugolix', 'Minor', 'Coadministration with lone inducers of CYP450 3A4 is unlikely to decrease the plasma concentrations of relugolix to a clinically significant extent.  In vitro, relugolix is metabolized primarily by CYP450 3A and, to a lesser extent, by CYP450 2C8.', 'DDInter', 'Coadministration with lone inducers of CYP450 3A4 is unlikely to decrease the plasma concentrations of relugolix to a clinically significant extent.  In vitro, relugolix is metabolized primarily by CYP450 3A and, to a lesser extent, by CYP450 2C8.  Relugolix is also a substrate for intestinal P-gp.  When relugolix was coadministered with rifampin, a combined P-gp and potent CYP450 3A inducer, relugolix peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 23% and 55%, respectively.  By contrast, no clinically significant differences in the pharmacokinetics of relugolix were observed when coadministered with enzalutamide, a strong CYP450 3A inducer that is not known to induce P-gp.', 'Metabolism, Absorption', 'Coadministration with lone inducers of CYP450 3A4 is unlikely to decrease the plasma concentrations of relugolix to a clinically significant extent.', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279643/', '', 'Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More', 'Nafarelin, Octreotide, Cetrorelix, Pasireotide, Ganirelix, Lanreotide, Gonadorelin, Anastrozole, Aminoglutethimide, Letrozole, Toremifene, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243204, 'Glycerol phenylbutyrate', 'Romidepsin', 'Moderate', 'Coadministration of histone deacetylase (HDAC) inhibitors and phenylbutyrate may lead to excess inhibition of HDAC and additive adverse effects.  According to the prescribing information for sodium phenylbutyrate combined with taurursodiol (ursodoxicoltaurine), phenylbutyrate is a pan-HDAC inhibitor', 'DDInter', 'The prescribing information for sodium phenylbutyrate combined with taurursodiol recommends avoiding concomitant use of phenylbutyrate and other HDAC inhibitors.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279644/', '', 'Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Agalsidase beta, Givosiran, More', 'Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243205, 'Glycerol phenylbutyrate', 'Triflupromazine', 'Moderate', 'Coadministration of glycerol phenylbutyrate may lead to increased concentrations of CYP450 2D6 substrates.  The proposed mechanism is inhibition of CYP450 2D6 by phenylbutyrate, the active moiety of glycerol phenylbutyrate, which has been shown to be an in vitro inhibitor of this isoenzyme.', 'DDInter', 'Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate.', 'Metabolism', 'Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279646/', '', 'Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More', 'Thiothixene, Amisulpride, Loxapine, Molindone, Droperidol, Lurasidone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243206, 'Glycerol phenylbutyrate', 'Alimemazine', 'Moderate', 'Coadministration of glycerol phenylbutyrate may lead to increased concentrations of CYP450 2D6 substrates.  The proposed mechanism is inhibition of CYP450 2D6 by phenylbutyrate, the active moiety of glycerol phenylbutyrate, which has been shown to be an in vitro inhibitor of this isoenzyme.', 'DDInter', 'Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate.', 'Metabolism', 'Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279647/', '', 'Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More', 'Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243207, 'Golimumab', 'Bacillus calmette-guerin substrain tice live antigen', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', 'DDInter', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279659/', '', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243208, 'Golimumab', 'Melphalan flufenamide', 'Major', 'The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL), which has primarily been reported in adolescent and young adult males receiving treatment for Crohn''s disease or ulcerative colitis.', 'DDInter', 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.  TNF blocker therapy should be discontinued if a serious infection or sepsis occurs.  Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.', 'Synergism', 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279675/', '', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243209, 'Golimumab', 'Promazine', 'Major', 'The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL), which has primarily been reported in adolescent and young adult males receiving treatment for Crohn''s disease or ulcerative colitis.', 'DDInter', 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.  TNF blocker therapy should be discontinued if a serious infection or sepsis occurs.  Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.', 'Synergism', 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279688/', '', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, More', 'Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243210, 'Golimumab', 'Varicella Zoster Vaccine (Recombinant)', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.', 'DDInter', 'In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual''s risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'In general, the U.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279716/', '', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243211, 'Guanadrel', 'Acetohexamide', 'Moderate', 'Postganglionic adrenergic blocking agents may potentiate the hypoglycemic effects of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides).  Limited data have demonstrated possible hypoglycemic activity with agents such as guanethidine and reserpine.  The mechanism may involve depletion of catecholamine stores from adrenergic nerve endings, which can interfere with glycogenolysis and other mechanisms related to regulation of blood glucose levels.', 'DDInter', 'Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  Insulin and oral antidiabetic dosages may require adjustment if an interaction is suspected.  Patients should be instructed about the need for regular monitoring of blood glucose levels and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked during antiadrenergic therapy.  However, other symptoms such as headache, dizziness, drowsiness, nausea, hunger, and sweating may be unaffected.  Patients should be observed for loss of glycemic control when antiadrenergic therapy is withdrawn.', 'Synergism', 'Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279739/', '', 'Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Semaglutide, Pioglitazone, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243212, 'Guanadrel', 'Bendroflumethiazide', 'Moderate', 'The hypotensive effects of thiazide diuretics and alpha-adrenergic blockers may be additive.  Postural hypotension may occur.', 'DDInter', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.  Patients should be advised to take the alpha-blocker at bedtime and to notify their physician if they experience dizziness or syncope while awake.', 'Synergism', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279741/', '', 'Furosemide, Bumetanide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243213, 'Guanadrel', 'Benzthiazide', 'Moderate', 'The hypotensive effects of thiazide diuretics and alpha-adrenergic blockers may be additive.  Postural hypotension may occur.', 'DDInter', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.  Patients should be advised to take the alpha-blocker at bedtime and to notify their physician if they experience dizziness or syncope while awake.', 'Synergism', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279742/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243214, 'Guanadrel', 'Carteolol', 'Moderate', 'Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons.  Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.', 'DDInter', 'Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.  Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.', 'Synergism', 'Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279744/', '', 'Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Acetazolamide, Brinzolamide, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243215, 'Guanadrel', 'Chloral hydrate', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279745/', '', 'Suvorexant, Methohexital, Methylphenobarbital, Pentobarbital, Valerian, Butabarbital, Secobarbital, Ramelteon, Lemborexant, Zopiclone, Amobarbital, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243216, 'Guanadrel', 'Chlormezanone', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279746/', '', 'Cyclobenzaprine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243217, 'Guanadrel', 'Chlorphenesin', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279747/', '', 'Salicylic acid, Fluconazole, Selenium Sulfide, Thiabendazole, Miconazole, Nystatin, Ciclopirox, Griseofulvin, Ketoconazole, Terbinafine, Econazole, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243218, 'Guanadrel', 'Ephedrine (nasal)', 'Moderate', 'Sympathomimetic amines may decrease the hypotensive effect of postganglionic adrenergic blocking agents, while the latter may potentiate the pharmacologic effects of direct-acting sympathomimetic amines (e.g., dobutamine, epinephrine, methoxamine, norepinephrine) but inhibit those that are primarily indirect-acting (e.g., mephentermine).  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings.  Therefore, they may sensitize adrenergic receptors to direct-acting sympathomimetics, but blunt the effects of indirect-acting agents whose activity is mediated through the release of catecholamines.  Guanethidine and reserpine have been reported to attenuate the pharmacologic effects (mydriasis, pressor response) induced by ephedrine and dopamine, both of which exhibit direct and indirect sympathomimetic activities (i.e., mixed-acting).  However, guanethidine intensified the mydriasis produced by phenylephrine, which is also thought to be mixed-acting.  Conversely, ephedrine has been shown to partially reverse the hypotensive effect of guanethidine.', 'DDInter', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Alternatives to postganglionic adrenergic blocking agents should be considered if patients are treated with sympathomimetic amines, since effects of the latter may be intensified or diminished depending on whether they are direct- or indirect-acting.  Most agents with indirect sympathomimetic activity are mixed-acting, thus it may be difficult to predict how they will be affected by postganglionic adrenergic blocking agents.  If the combination is used, blood pressure and heart rate should be monitored.', 'Antagonism', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279749/', '', 'Ketorolac, Homatropine, Atropine, Scopolamine, Methscopolamine, Tropicamide, Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243219, 'Halazepam', 'Guanadrel', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279750/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243220, 'Guanadrel', 'Diamorphine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279751/', '', 'Acamprosate, Naltrexone, Varenicline, Disulfiram, Methadone, Levacetylmethadol, Nalmefene, Nicotine, Buprenorphine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243221, 'Insulin human', 'Guanadrel', 'Moderate', 'Postganglionic adrenergic blocking agents may potentiate the hypoglycemic effects of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides).  Limited data have demonstrated possible hypoglycemic activity with agents such as guanethidine and reserpine.  The mechanism may involve depletion of catecholamine stores from adrenergic nerve endings, which can interfere with glycogenolysis and other mechanisms related to regulation of blood glucose levels.', 'DDInter', 'Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  Insulin and oral antidiabetic dosages may require adjustment if an interaction is suspected.  Patients should be instructed about the need for regular monitoring of blood glucose levels and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked during antiadrenergic therapy.  However, other symptoms such as headache, dizziness, drowsiness, nausea, hunger, and sweating may be unaffected.  Patients should be observed for loss of glycemic control when antiadrenergic therapy is withdrawn.', 'Synergism', 'Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279752/', '', 'Liraglutide, Lixisenatide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243222, 'Insulin aspart (aspart protamine)', 'Guanadrel', 'Moderate', 'Postganglionic adrenergic blocking agents may potentiate the hypoglycemic effects of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides).  Limited data have demonstrated possible hypoglycemic activity with agents such as guanethidine and reserpine.  The mechanism may involve depletion of catecholamine stores from adrenergic nerve endings, which can interfere with glycogenolysis and other mechanisms related to regulation of blood glucose levels.', 'DDInter', 'Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  Insulin and oral antidiabetic dosages may require adjustment if an interaction is suspected.  Patients should be instructed about the need for regular monitoring of blood glucose levels and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked during antiadrenergic therapy.  However, other symptoms such as headache, dizziness, drowsiness, nausea, hunger, and sweating may be unaffected.  Patients should be observed for loss of glycemic control when antiadrenergic therapy is withdrawn.', 'Synergism', 'Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279753/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243223, 'Insulin lispro (protamine)', 'Guanadrel', 'Moderate', 'Postganglionic adrenergic blocking agents may potentiate the hypoglycemic effects of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides).  Limited data have demonstrated possible hypoglycemic activity with agents such as guanethidine and reserpine.  The mechanism may involve depletion of catecholamine stores from adrenergic nerve endings, which can interfere with glycogenolysis and other mechanisms related to regulation of blood glucose levels.', 'DDInter', 'Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  Insulin and oral antidiabetic dosages may require adjustment if an interaction is suspected.  Patients should be instructed about the need for regular monitoring of blood glucose levels and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked during antiadrenergic therapy.  However, other symptoms such as headache, dizziness, drowsiness, nausea, hunger, and sweating may be unaffected.  Patients should be observed for loss of glycemic control when antiadrenergic therapy is withdrawn.', 'Synergism', 'Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279754/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243224, 'Guanadrel', 'Levmetamfetamine (nasal)', 'Moderate', 'Sympathomimetic amines may decrease the hypotensive effect of postganglionic adrenergic blocking agents, while the latter may potentiate the pharmacologic effects of direct-acting sympathomimetic amines (e.g., dobutamine, epinephrine, methoxamine, norepinephrine) but inhibit those that are primarily indirect-acting (e.g., mephentermine).  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings.  Therefore, they may sensitize adrenergic receptors to direct-acting sympathomimetics, but blunt the effects of indirect-acting agents whose activity is mediated through the release of catecholamines.  Guanethidine and reserpine have been reported to attenuate the pharmacologic effects (mydriasis, pressor response) induced by ephedrine and dopamine, both of which exhibit direct and indirect sympathomimetic activities (i.e., mixed-acting).  However, guanethidine intensified the mydriasis produced by phenylephrine, which is also thought to be mixed-acting.  Conversely, ephedrine has been shown to partially reverse the hypotensive effect of guanethidine.', 'DDInter', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Alternatives to postganglionic adrenergic blocking agents should be considered if patients are treated with sympathomimetic amines, since effects of the latter may be intensified or diminished depending on whether they are direct- or indirect-acting.  Most agents with indirect sympathomimetic activity are mixed-acting, thus it may be difficult to predict how they will be affected by postganglionic adrenergic blocking agents.  If the combination is used, blood pressure and heart rate should be monitored.', 'Antagonism', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279755/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243225, 'Guanadrel', 'Levobetaxolol (ophthalmic)', 'Moderate', 'Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons.  Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.', 'DDInter', 'Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.  Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.', 'Synergism', 'Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279756/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243226, 'Guanadrel', 'Mazindol', 'Moderate', 'Central nervous system (CNS) stimulants, particularly the amphetamines, may decrease the hypotensive effect of postganglionic adrenergic blocking agents such as guanadrel, guanethidine and rauwolfia alkaloids, which work by depleting catecholamine stores from adrenergic nerve endings.  CNS stimulants can have peripheral sympathetic activity, thus they may elevate blood pressure on their own as well as antagonize some of the antiadrenergic effect produced by these hypotensive agents.  Amphetamines reportedly also may displace the blocking agent, guanethidine, and inhibit its uptake by adrenergic neurons.  Other mechanisms have also been proposed.  In addition to diminished hypotensive response, the interaction has also been reported to produce hypotension and ventricular tachycardia in a patient stabilized on guanethidine shortly after initiating treatment with methylphenidate.', 'DDInter', 'Alternatives to postganglionic adrenergic blocking agents should be considered in hypertensive patients treated with CNS stimulants.  If the combination is used, blood pressure and heart rate should be monitored.', 'Antagonism', 'Alternatives to postganglionic adrenergic blocking agents should be considered in hypertensive patients treated with CNS stimulants.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279758/', '', 'Dexfenfluramine, Naltrexone, Fenfluramine, Orlistat, Lorcaserin, Sibutramine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243227, 'Guanadrel', 'Mephentermine', 'Moderate', 'Sympathomimetic amines may decrease the hypotensive effect of postganglionic adrenergic blocking agents, while the latter may potentiate the pharmacologic effects of direct-acting sympathomimetic amines (e.g., dobutamine, epinephrine, methoxamine, norepinephrine) but inhibit those that are primarily indirect-acting (e.g., mephentermine).  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings.  Therefore, they may sensitize adrenergic receptors to direct-acting sympathomimetics, but blunt the effects of indirect-acting agents whose activity is mediated through the release of catecholamines.  Guanethidine and reserpine have been reported to attenuate the pharmacologic effects (mydriasis, pressor response) induced by ephedrine and dopamine, both of which exhibit direct and indirect sympathomimetic activities (i.e., mixed-acting).  However, guanethidine intensified the mydriasis produced by phenylephrine, which is also thought to be mixed-acting.  Conversely, ephedrine has been shown to partially reverse the hypotensive effect of guanethidine.', 'DDInter', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Alternatives to postganglionic adrenergic blocking agents should be considered if patients are treated with sympathomimetic amines, since effects of the latter may be intensified or diminished depending on whether they are direct- or indirect-acting.  Most agents with indirect sympathomimetic activity are mixed-acting, thus it may be difficult to predict how they will be affected by postganglionic adrenergic blocking agents.  If the combination is used, blood pressure and heart rate should be monitored.', 'Antagonism', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279759/', '', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243228, 'Guanadrel', 'Metaraminol', 'Moderate', 'Sympathomimetic amines may decrease the hypotensive effect of postganglionic adrenergic blocking agents, while the latter may potentiate the pharmacologic effects of direct-acting sympathomimetic amines (e.g., dobutamine, epinephrine, methoxamine, norepinephrine) but inhibit those that are primarily indirect-acting (e.g., mephentermine).  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings.  Therefore, they may sensitize adrenergic receptors to direct-acting sympathomimetics, but blunt the effects of indirect-acting agents whose activity is mediated through the release of catecholamines.  Guanethidine and reserpine have been reported to attenuate the pharmacologic effects (mydriasis, pressor response) induced by ephedrine and dopamine, both of which exhibit direct and indirect sympathomimetic activities (i.e., mixed-acting).  However, guanethidine intensified the mydriasis produced by phenylephrine, which is also thought to be mixed-acting.  Conversely, ephedrine has been shown to partially reverse the hypotensive effect of guanethidine.', 'DDInter', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Alternatives to postganglionic adrenergic blocking agents should be considered if patients are treated with sympathomimetic amines, since effects of the latter may be intensified or diminished depending on whether they are direct- or indirect-acting.  Most agents with indirect sympathomimetic activity are mixed-acting, thus it may be difficult to predict how they will be affected by postganglionic adrenergic blocking agents.  If the combination is used, blood pressure and heart rate should be monitored.', 'Antagonism', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279760/', '', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243229, 'Guanadrel', 'Methdilazine', 'Moderate', 'Phenothiazines may inhibit the antihypertensive effect of guanethidine, probably through inhibition of guanethidine neuronal uptake.', 'DDInter', 'This combination should generally be avoided.  An alternative antihypertensive regimen may be necessary for patients who must take phenothiazine antipsychotics.  If patients do receive a phenothiazine with an adrenergic neurone blocker, their blood pressure should be monitored closely.  The dosage of the antihypertensive may require adjustment.', 'Distribution', 'This combination should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279761/', '', 'Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Fexofenadine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243230, 'Guanadrel', 'Methotrimeprazine', 'Moderate', 'Phenothiazines may inhibit the antihypertensive effect of guanethidine, probably through inhibition of guanethidine neuronal uptake.', 'DDInter', 'This combination should generally be avoided.  An alternative antihypertensive regimen may be necessary for patients who must take phenothiazine antipsychotics.  If patients do receive a phenothiazine with an adrenergic neurone blocker, their blood pressure should be monitored closely.  The dosage of the antihypertensive may require adjustment.', 'Distribution', 'This combination should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279762/', '', 'Droperidol, Pimozide, Pimavanserin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243231, 'Guanadrel', 'Methoxamine', 'Moderate', 'Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished.  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.', 'DDInter', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines.  If the combination is used, blood pressure and heart rate should be closely monitored.', 'Antagonism', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279763/', '', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243232, 'Guanadrel', 'Naphazoline (nasal)', 'Moderate', 'Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished.  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.', 'DDInter', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines.  If the combination is used, blood pressure and heart rate should be closely monitored.', 'Antagonism', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279764/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243233, 'Guanadrel', 'Paraldehyde', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279765/', '', 'Suvorexant, Methohexital, Methylphenobarbital, Pentobarbital, Valerian, Butabarbital, Secobarbital, Ramelteon, Lemborexant, Zopiclone, Amobarbital, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243234, 'Guanadrel', 'Penbutolol', 'Moderate', 'Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons.  Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.', 'DDInter', 'Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.  Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.', 'Synergism', 'Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279766/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243235, 'Guanadrel', 'Promazine', 'Moderate', 'Phenothiazines may inhibit the antihypertensive effect of guanethidine, probably through inhibition of guanethidine neuronal uptake.', 'DDInter', 'This combination should generally be avoided.  An alternative antihypertensive regimen may be necessary for patients who must take phenothiazine antipsychotics.  If patients do receive a phenothiazine with an adrenergic neurone blocker, their blood pressure should be monitored closely.  The dosage of the antihypertensive may require adjustment.', 'Distribution', 'This combination should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279767/', '', 'Droperidol, Pimozide, Pimavanserin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243236, 'Guanadrel', 'Propiomazine', 'Moderate', 'Phenothiazines may inhibit the antihypertensive effect of guanethidine, probably through inhibition of guanethidine neuronal uptake.', 'DDInter', 'This combination should generally be avoided.  An alternative antihypertensive regimen may be necessary for patients who must take phenothiazine antipsychotics.  If patients do receive a phenothiazine with an adrenergic neurone blocker, their blood pressure should be monitored closely.  The dosage of the antihypertensive may require adjustment.', 'Distribution', 'This combination should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279768/', '', 'Suvorexant, Methohexital, Methylphenobarbital, Pentobarbital, Valerian, Butabarbital, Secobarbital, Ramelteon, Lemborexant, Zopiclone, Amobarbital, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243237, 'Guanadrel', 'Ritodrine', 'Moderate', 'Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished.  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.', 'DDInter', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines.  If the combination is used, blood pressure and heart rate should be closely monitored.', 'Antagonism', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279769/', '', 'Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Naproxen, Ibuprofen', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243238, 'Guanadrel', 'Trichlormethiazide', 'Moderate', 'The hypotensive effects of thiazide diuretics and alpha-adrenergic blockers may be additive.  Postural hypotension may occur.', 'DDInter', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.  Patients should be advised to take the alpha-blocker at bedtime and to notify their physician if they experience dizziness or syncope while awake.', 'Synergism', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279770/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243239, 'Guanadrel', 'Triflupromazine', 'Moderate', 'Phenothiazines may inhibit the antihypertensive effect of guanethidine, probably through inhibition of guanethidine neuronal uptake.', 'DDInter', 'This combination should generally be avoided.  An alternative antihypertensive regimen may be necessary for patients who must take phenothiazine antipsychotics.  If patients do receive a phenothiazine with an adrenergic neurone blocker, their blood pressure should be monitored closely.  The dosage of the antihypertensive may require adjustment.', 'Distribution', 'This combination should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279771/', '', 'Droperidol, Pimozide, Pimavanserin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243240, 'Guanadrel', 'Alimemazine', 'Moderate', 'Phenothiazines may inhibit the antihypertensive effect of guanethidine, probably through inhibition of guanethidine neuronal uptake.', 'DDInter', 'This combination should generally be avoided.  An alternative antihypertensive regimen may be necessary for patients who must take phenothiazine antipsychotics.  If patients do receive a phenothiazine with an adrenergic neurone blocker, their blood pressure should be monitored closely.  The dosage of the antihypertensive may require adjustment.', 'Distribution', 'This combination should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279772/', '', 'Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Fexofenadine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243241, 'Guanadrel', 'Xylometazoline (nasal)', 'Moderate', 'Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished.  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.', 'DDInter', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines.  If the combination is used, blood pressure and heart rate should be closely monitored.', 'Antagonism', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279774/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243242, 'Guanethidine', 'Acetohexamide', 'Moderate', 'Postganglionic adrenergic blocking agents may potentiate the hypoglycemic effects of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides).  Limited data have demonstrated possible hypoglycemic activity with agents such as guanethidine and reserpine.  The mechanism may involve depletion of catecholamine stores from adrenergic nerve endings, which can interfere with glycogenolysis and other mechanisms related to regulation of blood glucose levels.', 'DDInter', 'Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  Insulin and oral antidiabetic dosages may require adjustment if an interaction is suspected.  Patients should be instructed about the need for regular monitoring of blood glucose levels and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked during antiadrenergic therapy.  However, other symptoms such as headache, dizziness, drowsiness, nausea, hunger, and sweating may be unaffected.  Patients should be observed for loss of glycemic control when antiadrenergic therapy is withdrawn.', 'Synergism', 'Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279775/', '', 'Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Semaglutide, Pioglitazone, More', 'Latanoprost, Apraclonidine, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Bimatoprost, Travoprost, Carteolol, Brinzolamide, Brimonidine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243243, 'Guanethidine', 'Bendroflumethiazide', 'Moderate', 'The hypotensive effects of thiazide diuretics and alpha-adrenergic blockers may be additive.  Postural hypotension may occur.', 'DDInter', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.  Patients should be advised to take the alpha-blocker at bedtime and to notify their physician if they experience dizziness or syncope while awake.', 'Synergism', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279776/', '', 'Furosemide, Bumetanide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More', 'Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Carteolol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243244, 'Guanethidine', 'Benzthiazide', 'Moderate', 'The hypotensive effects of thiazide diuretics and alpha-adrenergic blockers may be additive.  Postural hypotension may occur.', 'DDInter', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.  Patients should be advised to take the alpha-blocker at bedtime and to notify their physician if they experience dizziness or syncope while awake.', 'Synergism', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279777/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More', 'Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Carteolol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243245, 'Guanethidine', 'Carteolol', 'Moderate', 'Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons.  Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.', 'DDInter', 'Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.  Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.', 'Synergism', 'Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279779/', '', 'Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Acetazolamide, Brinzolamide, More', 'Latanoprost, Methazolamide, Acetylcholine, Betaxolol, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, Acetazolamide, Brimonidine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243246, 'Guanethidine', 'Chloral hydrate', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279780/', '', 'Suvorexant, Triazolam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Ramelteon, Lemborexant, Ethchlorvynol, Zopiclone, More', 'Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243247, 'Guanethidine', 'Ephedrine (nasal)', 'Moderate', 'Sympathomimetic amines may decrease the hypotensive effect of postganglionic adrenergic blocking agents, while the latter may potentiate the pharmacologic effects of direct-acting sympathomimetic amines (e.g., dobutamine, epinephrine, methoxamine, norepinephrine) but inhibit those that are primarily indirect-acting (e.g., mephentermine).  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings.  Therefore, they may sensitize adrenergic receptors to direct-acting sympathomimetics, but blunt the effects of indirect-acting agents whose activity is mediated through the release of catecholamines.  Guanethidine and reserpine have been reported to attenuate the pharmacologic effects (mydriasis, pressor response) induced by ephedrine and dopamine, both of which exhibit direct and indirect sympathomimetic activities (i.e., mixed-acting).  However, guanethidine intensified the mydriasis produced by phenylephrine, which is also thought to be mixed-acting.  Conversely, ephedrine has been shown to partially reverse the hypotensive effect of guanethidine.', 'DDInter', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Alternatives to postganglionic adrenergic blocking agents should be considered if patients are treated with sympathomimetic amines, since effects of the latter may be intensified or diminished depending on whether they are direct- or indirect-acting.  Most agents with indirect sympathomimetic activity are mixed-acting, thus it may be difficult to predict how they will be affected by postganglionic adrenergic blocking agents.  If the combination is used, blood pressure and heart rate should be monitored.', 'Antagonism', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279782/', '', 'Ketorolac, Homatropine, Atropine, Scopolamine, Methscopolamine, Tropicamide, Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, More', 'Neostigmine, Brimonidine, Timolol, Levobunolol, Methazolamide, Pilocarpine, Physostigmine, Bimatoprost, Brinzolamide, Acetylcholine, Betaxolol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243248, 'Guanethidine', 'Diamorphine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279783/', '', 'Acamprosate, Naltrexone, Varenicline, Disulfiram, Levacetylmethadol, Nalmefene, Nicotine', 'Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243249, 'Insulin human', 'Guanethidine', 'Moderate', 'Postganglionic adrenergic blocking agents may potentiate the hypoglycemic effects of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides).  Limited data have demonstrated possible hypoglycemic activity with agents such as guanethidine and reserpine.  The mechanism may involve depletion of catecholamine stores from adrenergic nerve endings, which can interfere with glycogenolysis and other mechanisms related to regulation of blood glucose levels.', 'DDInter', 'Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  Insulin and oral antidiabetic dosages may require adjustment if an interaction is suspected.  Patients should be instructed about the need for regular monitoring of blood glucose levels and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked during antiadrenergic therapy.  However, other symptoms such as headache, dizziness, drowsiness, nausea, hunger, and sweating may be unaffected.  Patients should be observed for loss of glycemic control when antiadrenergic therapy is withdrawn.', 'Synergism', 'Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279784/', '', 'Latanoprost, Apraclonidine, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Bimatoprost, Travoprost, Brinzolamide, Brimonidine, Levobunolol, More', 'Liraglutide, Lixisenatide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243250, 'Insulin aspart (aspart protamine)', 'Guanethidine', 'Moderate', 'Postganglionic adrenergic blocking agents may potentiate the hypoglycemic effects of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides).  Limited data have demonstrated possible hypoglycemic activity with agents such as guanethidine and reserpine.  The mechanism may involve depletion of catecholamine stores from adrenergic nerve endings, which can interfere with glycogenolysis and other mechanisms related to regulation of blood glucose levels.', 'DDInter', 'Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  Insulin and oral antidiabetic dosages may require adjustment if an interaction is suspected.  Patients should be instructed about the need for regular monitoring of blood glucose levels and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked during antiadrenergic therapy.  However, other symptoms such as headache, dizziness, drowsiness, nausea, hunger, and sweating may be unaffected.  Patients should be observed for loss of glycemic control when antiadrenergic therapy is withdrawn.', 'Synergism', 'Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279785/', '', 'Latanoprost, Apraclonidine, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Bimatoprost, Travoprost, Brinzolamide, Brimonidine, Levobunolol, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243251, 'Insulin lispro (protamine)', 'Guanethidine', 'Moderate', 'Postganglionic adrenergic blocking agents may potentiate the hypoglycemic effects of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides).  Limited data have demonstrated possible hypoglycemic activity with agents such as guanethidine and reserpine.  The mechanism may involve depletion of catecholamine stores from adrenergic nerve endings, which can interfere with glycogenolysis and other mechanisms related to regulation of blood glucose levels.', 'DDInter', 'Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  Insulin and oral antidiabetic dosages may require adjustment if an interaction is suspected.  Patients should be instructed about the need for regular monitoring of blood glucose levels and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked during antiadrenergic therapy.  However, other symptoms such as headache, dizziness, drowsiness, nausea, hunger, and sweating may be unaffected.  Patients should be observed for loss of glycemic control when antiadrenergic therapy is withdrawn.', 'Synergism', 'Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279786/', '', 'Latanoprost, Apraclonidine, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Bimatoprost, Travoprost, Brinzolamide, Brimonidine, Levobunolol, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243252, 'Guanethidine', 'Levmetamfetamine (nasal)', 'Moderate', 'Sympathomimetic amines may decrease the hypotensive effect of postganglionic adrenergic blocking agents, while the latter may potentiate the pharmacologic effects of direct-acting sympathomimetic amines (e.g., dobutamine, epinephrine, methoxamine, norepinephrine) but inhibit those that are primarily indirect-acting (e.g., mephentermine).  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings.  Therefore, they may sensitize adrenergic receptors to direct-acting sympathomimetics, but blunt the effects of indirect-acting agents whose activity is mediated through the release of catecholamines.  Guanethidine and reserpine have been reported to attenuate the pharmacologic effects (mydriasis, pressor response) induced by ephedrine and dopamine, both of which exhibit direct and indirect sympathomimetic activities (i.e., mixed-acting).  However, guanethidine intensified the mydriasis produced by phenylephrine, which is also thought to be mixed-acting.  Conversely, ephedrine has been shown to partially reverse the hypotensive effect of guanethidine.', 'DDInter', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Alternatives to postganglionic adrenergic blocking agents should be considered if patients are treated with sympathomimetic amines, since effects of the latter may be intensified or diminished depending on whether they are direct- or indirect-acting.  Most agents with indirect sympathomimetic activity are mixed-acting, thus it may be difficult to predict how they will be affected by postganglionic adrenergic blocking agents.  If the combination is used, blood pressure and heart rate should be monitored.', 'Antagonism', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279787/', '', 'Neostigmine, Brimonidine, Timolol, Levobunolol, Methazolamide, Pilocarpine, Physostigmine, Bimatoprost, Brinzolamide, Acetylcholine, Betaxolol, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243253, 'Guanethidine', 'Levobetaxolol (ophthalmic)', 'Moderate', 'Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons.  Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.', 'DDInter', 'Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.  Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.', 'Synergism', 'Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279788/', '', 'Latanoprost, Methazolamide, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, Acetazolamide, Brimonidine, Levobunolol, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243254, 'Guanethidine', 'Mazindol', 'Moderate', 'Central nervous system (CNS) stimulants, particularly the amphetamines, may decrease the hypotensive effect of postganglionic adrenergic blocking agents such as guanadrel, guanethidine and rauwolfia alkaloids, which work by depleting catecholamine stores from adrenergic nerve endings.  CNS stimulants can have peripheral sympathetic activity, thus they may elevate blood pressure on their own as well as antagonize some of the antiadrenergic effect produced by these hypotensive agents.  Amphetamines reportedly also may displace the blocking agent, guanethidine, and inhibit its uptake by adrenergic neurons.  Other mechanisms have also been proposed.  In addition to diminished hypotensive response, the interaction has also been reported to produce hypotension and ventricular tachycardia in a patient stabilized on guanethidine shortly after initiating treatment with methylphenidate.', 'DDInter', 'Alternatives to postganglionic adrenergic blocking agents should be considered in hypertensive patients treated with CNS stimulants.  If the combination is used, blood pressure and heart rate should be monitored.', 'Antagonism', 'Alternatives to postganglionic adrenergic blocking agents should be considered in hypertensive patients treated with CNS stimulants.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279790/', '', 'Latanoprost, Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Betaxolol, Diclofenamide, Bimatoprost, More', 'Dexfenfluramine, Naltrexone, Fenfluramine, Orlistat, Lorcaserin, Sibutramine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243255, 'Guanethidine', 'Mephentermine', 'Moderate', 'Sympathomimetic amines may decrease the hypotensive effect of postganglionic adrenergic blocking agents, while the latter may potentiate the pharmacologic effects of direct-acting sympathomimetic amines (e.g., dobutamine, epinephrine, methoxamine, norepinephrine) but inhibit those that are primarily indirect-acting (e.g., mephentermine).  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings.  Therefore, they may sensitize adrenergic receptors to direct-acting sympathomimetics, but blunt the effects of indirect-acting agents whose activity is mediated through the release of catecholamines.  Guanethidine and reserpine have been reported to attenuate the pharmacologic effects (mydriasis, pressor response) induced by ephedrine and dopamine, both of which exhibit direct and indirect sympathomimetic activities (i.e., mixed-acting).  However, guanethidine intensified the mydriasis produced by phenylephrine, which is also thought to be mixed-acting.  Conversely, ephedrine has been shown to partially reverse the hypotensive effect of guanethidine.', 'DDInter', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Alternatives to postganglionic adrenergic blocking agents should be considered if patients are treated with sympathomimetic amines, since effects of the latter may be intensified or diminished depending on whether they are direct- or indirect-acting.  Most agents with indirect sympathomimetic activity are mixed-acting, thus it may be difficult to predict how they will be affected by postganglionic adrenergic blocking agents.  If the combination is used, blood pressure and heart rate should be monitored.', 'Antagonism', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279791/', '', 'Latanoprost, Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, More', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243256, 'Guanethidine', 'Metaraminol', 'Moderate', 'Sympathomimetic amines may decrease the hypotensive effect of postganglionic adrenergic blocking agents, while the latter may potentiate the pharmacologic effects of direct-acting sympathomimetic amines (e.g., dobutamine, epinephrine, methoxamine, norepinephrine) but inhibit those that are primarily indirect-acting (e.g., mephentermine).  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings.  Therefore, they may sensitize adrenergic receptors to direct-acting sympathomimetics, but blunt the effects of indirect-acting agents whose activity is mediated through the release of catecholamines.  Guanethidine and reserpine have been reported to attenuate the pharmacologic effects (mydriasis, pressor response) induced by ephedrine and dopamine, both of which exhibit direct and indirect sympathomimetic activities (i.e., mixed-acting).  However, guanethidine intensified the mydriasis produced by phenylephrine, which is also thought to be mixed-acting.  Conversely, ephedrine has been shown to partially reverse the hypotensive effect of guanethidine.', 'DDInter', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Alternatives to postganglionic adrenergic blocking agents should be considered if patients are treated with sympathomimetic amines, since effects of the latter may be intensified or diminished depending on whether they are direct- or indirect-acting.  Most agents with indirect sympathomimetic activity are mixed-acting, thus it may be difficult to predict how they will be affected by postganglionic adrenergic blocking agents.  If the combination is used, blood pressure and heart rate should be monitored.', 'Antagonism', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279792/', '', 'Latanoprost, Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, More', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243257, 'Guanethidine', 'Methdilazine', 'Moderate', 'Phenothiazines may inhibit the antihypertensive effect of guanethidine, probably through inhibition of guanethidine neuronal uptake.', 'DDInter', 'This combination should generally be avoided.  An alternative antihypertensive regimen may be necessary for patients who must take phenothiazine antipsychotics.  If patients do receive a phenothiazine with an adrenergic neurone blocker, their blood pressure should be monitored closely.  The dosage of the antihypertensive may require adjustment.', 'Distribution', 'This combination should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279793/', '', 'Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, Acetazolamide, Brimonidine, More', 'Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Fexofenadine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243258, 'Guanethidine', 'Methotrimeprazine', 'Moderate', 'Phenothiazines may inhibit the antihypertensive effect of guanethidine, probably through inhibition of guanethidine neuronal uptake.', 'DDInter', 'This combination should generally be avoided.  An alternative antihypertensive regimen may be necessary for patients who must take phenothiazine antipsychotics.  If patients do receive a phenothiazine with an adrenergic neurone blocker, their blood pressure should be monitored closely.  The dosage of the antihypertensive may require adjustment.', 'Distribution', 'This combination should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279794/', '', 'Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, Acetazolamide, Brimonidine, More', 'Droperidol, Pimozide, Pimavanserin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243259, 'Guanethidine', 'Methoxamine', 'Moderate', 'Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished.  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.', 'DDInter', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines.  If the combination is used, blood pressure and heart rate should be closely monitored.', 'Antagonism', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279795/', '', 'Neostigmine, Brimonidine, Timolol, Levobunolol, Methazolamide, Pilocarpine, Physostigmine, Bimatoprost, Brinzolamide, Acetylcholine, Betaxolol, More', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243260, 'Guanethidine', 'Naphazoline (nasal)', 'Moderate', 'Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished.  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.', 'DDInter', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines.  If the combination is used, blood pressure and heart rate should be closely monitored.', 'Antagonism', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279796/', '', 'Neostigmine, Brimonidine, Timolol, Levobunolol, Methazolamide, Pilocarpine, Physostigmine, Bimatoprost, Brinzolamide, Acetylcholine, Betaxolol, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243261, 'Guanethidine', 'Paraldehyde', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279797/', '', 'Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, More', 'Suvorexant, Triazolam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Ramelteon, Lemborexant, Ethchlorvynol, Zopiclone, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243262, 'Guanethidine', 'Penbutolol', 'Moderate', 'Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons.  Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.', 'DDInter', 'Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.  Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.', 'Synergism', 'Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279798/', '', 'Latanoprost, Methazolamide, Acetylcholine, Betaxolol, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, Acetazolamide, Brimonidine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243263, 'Guanethidine', 'Promazine', 'Moderate', 'Phenothiazines may inhibit the antihypertensive effect of guanethidine, probably through inhibition of guanethidine neuronal uptake.', 'DDInter', 'This combination should generally be avoided.  An alternative antihypertensive regimen may be necessary for patients who must take phenothiazine antipsychotics.  If patients do receive a phenothiazine with an adrenergic neurone blocker, their blood pressure should be monitored closely.  The dosage of the antihypertensive may require adjustment.', 'Distribution', 'This combination should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279799/', '', 'Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, Brimonidine, Levobunolol, More', 'Droperidol, Pimozide, Pimavanserin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243264, 'Guanethidine', 'Propiomazine', 'Moderate', 'Phenothiazines may inhibit the antihypertensive effect of guanethidine, probably through inhibition of guanethidine neuronal uptake.', 'DDInter', 'This combination should generally be avoided.  An alternative antihypertensive regimen may be necessary for patients who must take phenothiazine antipsychotics.  If patients do receive a phenothiazine with an adrenergic neurone blocker, their blood pressure should be monitored closely.  The dosage of the antihypertensive may require adjustment.', 'Distribution', 'This combination should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279800/', '', 'Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, Acetazolamide, Brimonidine, More', 'Suvorexant, Triazolam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Ramelteon, Lemborexant, Ethchlorvynol, Zopiclone, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243265, 'Guanethidine', 'Ritodrine', 'Moderate', 'Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished.  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.', 'DDInter', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines.  If the combination is used, blood pressure and heart rate should be closely monitored.', 'Antagonism', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279801/', '', 'Latanoprost, Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, More', 'Bremelanotide, Flibanserin, Black cohosh, Bromocriptine, Naproxen, Ibuprofen', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243266, 'Guanethidine', 'Trichlormethiazide', 'Moderate', 'The hypotensive effects of thiazide diuretics and alpha-adrenergic blockers may be additive.  Postural hypotension may occur.', 'DDInter', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.  Patients should be advised to take the alpha-blocker at bedtime and to notify their physician if they experience dizziness or syncope while awake.', 'Synergism', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279802/', '', 'Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Carteolol, More', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243267, 'Guanethidine', 'Triflupromazine', 'Moderate', 'Phenothiazines may inhibit the antihypertensive effect of guanethidine, probably through inhibition of guanethidine neuronal uptake.', 'DDInter', 'This combination should generally be avoided.  An alternative antihypertensive regimen may be necessary for patients who must take phenothiazine antipsychotics.  If patients do receive a phenothiazine with an adrenergic neurone blocker, their blood pressure should be monitored closely.  The dosage of the antihypertensive may require adjustment.', 'Distribution', 'This combination should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279803/', '', 'Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, Acetazolamide, Brimonidine, More', 'Droperidol, Pimozide, Pimavanserin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243268, 'Guanethidine', 'Alimemazine', 'Moderate', 'Phenothiazines may inhibit the antihypertensive effect of guanethidine, probably through inhibition of guanethidine neuronal uptake.', 'DDInter', 'This combination should generally be avoided.  An alternative antihypertensive regimen may be necessary for patients who must take phenothiazine antipsychotics.  If patients do receive a phenothiazine with an adrenergic neurone blocker, their blood pressure should be monitored closely.  The dosage of the antihypertensive may require adjustment.', 'Distribution', 'This combination should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279804/', '', 'Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Fexofenadine, More', 'Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, Acetazolamide, Brimonidine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243269, 'Guanethidine', 'Xylometazoline (nasal)', 'Moderate', 'Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished.  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.', 'DDInter', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines.  If the combination is used, blood pressure and heart rate should be closely monitored.', 'Antagonism', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279806/', '', 'Neostigmine, Brimonidine, Timolol, Levobunolol, Methazolamide, Pilocarpine, Physostigmine, Bimatoprost, Brinzolamide, Acetylcholine, Betaxolol, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243270, 'Guanfacine', 'Acrivastine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279808/', '', 'Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Fexofenadine, Meclizine, More', 'Rauwolfia serpentina root, Reserpine, Deserpidine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243271, 'Guanfacine', 'Melatonin', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279813/', '', 'Rauwolfia serpentina root, Reserpine, Deserpidine', 'Nitrazepam, Thiopental, Eszopiclone, Ramelteon, Estazolam, Zopiclone, Tasimelteon, Valerian', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243272, 'Guanidine', 'Ambenonium', 'Moderate', 'A synergistic effect may be expected when acetylcholinesterase inhibitors are administered concurrently with other cholinesterase inhibitors or cholinergic agonists.', 'DDInter', 'Monitoring for excessive cholinergic effects and seizure activity is recommended.  Patients should be advised to notify their physician if they experience nausea, vomiting, diarrhea, abdominal pain, increased salivation, cold sweats, slow or irregular heartbeat, muscle weakness or cramps, dizziness, headache, seizures, or respiratory distress.', 'Synergism', 'Monitoring for excessive cholinergic effects and seizure activity is recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279823/', '', 'Pilocarpine, Cevimeline', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243273, 'Guanidine', 'Pyridostigmine', 'Moderate', 'A synergistic effect may be expected when acetylcholinesterase inhibitors are administered concurrently with other cholinesterase inhibitors or cholinergic agonists.', 'DDInter', 'Monitoring for excessive cholinergic effects and seizure activity is recommended.  Patients should be advised to notify their physician if they experience nausea, vomiting, diarrhea, abdominal pain, increased salivation, cold sweats, slow or irregular heartbeat, muscle weakness or cramps, dizziness, headache, seizures, or respiratory distress.', 'Synergism', 'Monitoring for excessive cholinergic effects and seizure activity is recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279824/', '', 'Pilocarpine, Cevimeline', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243274, 'Guselkumab', 'Bacillus calmette-guerin substrain tice live antigen', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', 'DDInter', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279826/', '', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243275, 'Guselkumab', 'Melphalan flufenamide', 'Moderate', 'The use of interleukin blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections.', 'DDInter', 'Caution is advised when interleukin inhibitors are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges such as immunosuppressants or antineoplastic agents.  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of interleukin inhibitor therapy, and the dosage(s) of these drugs adjusted accordingly.  Clinicians should note that the effects of interleukin inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Synergism', 'Caution is advised when interleukin inhibitors are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges such as immunosuppressants or antineoplastic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279840/', '', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', 'Temozolomide, Thiotepa, Carmustine, Cyclophosphamide, Busulfan, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Ifosfamide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243276, 'Guselkumab', 'Varicella Zoster Vaccine (Recombinant)', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.', 'DDInter', 'In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual''s risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'In general, the U.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/279876/', '', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243277, 'Acrivastine', 'Triazolam', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/280130/', '', 'Ketotifen, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine', 'Nitrazepam, Zopiclone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243278, 'Chlorcyclizine', 'Triazolam', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/280133/', '', 'Ketotifen, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine', 'Temazepam, Butabarbital, Chloral hydrate, Nitrazepam, Paraldehyde, Amobarbital, Meprobamate, Butalbital, Eszopiclone, Estazolam, Methylphenobarbital, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243279, 'Halazepam', 'Triazolam', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/280136/', '', 'Nitrazepam, Chloral hydrate, Paraldehyde, Propiomazine, Zopiclone', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243280, 'Triazolam', 'Osilodrostat', 'Moderate', 'Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.', 'DDInter', 'Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/280143/', '', 'Temazepam, Remimazolam, Chloral hydrate, Nitrazepam, Thiopental, Paraldehyde, Propiomazine, Meprobamate, Scopolamine, Dexmedetomidine, Methohexital, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243281, 'Triazolam', 'Paraldehyde', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/280144/', '', 'Triazolam', 'Chloral hydrate, Nitrazepam, Thiopental, Paraldehyde, Propiomazine, Ethchlorvynol, Zolpidem, Zopiclone, Pentobarbital, Zaleplon', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243282, 'Triazolam', 'Pentobarbital', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/280145/', '', 'Triazolam', 'Nitrazepam, Paraldehyde, Ethchlorvynol, Zopiclone, Pentobarbital, Zaleplon', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243283, 'Halofantrine', 'Abarelix', 'Major', 'Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses.  QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.  The manufacturer recommends performing an ECG before initiating halofantrine therapy and monitoring cardiac rhythm during and for 8 to 12 hours after completion of therapy.', 'Synergism', 'Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/280151/', '', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243284, 'Halofantrine', 'Astemizole', 'Major', 'Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses.  QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.  The manufacturer recommends performing an ECG before initiating halofantrine therapy and monitoring cardiac rhythm during and for 8 to 12 hours after completion of therapy.', 'Synergism', 'Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/280152/', '', 'Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More', 'Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243285, 'Halofantrine', 'Bepridil', 'Major', 'Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses.  QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.  The manufacturer recommends performing an ECG before initiating halofantrine therapy and monitoring cardiac rhythm during and for 8 to 12 hours after completion of therapy.', 'Synergism', 'Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/280153/', '', 'Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243286, 'Halofantrine', 'Cisapride', 'Major', 'Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses.  QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.  The manufacturer recommends performing an ECG before initiating halofantrine therapy and monitoring cardiac rhythm during and for 8 to 12 hours after completion of therapy.', 'Synergism', 'Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/280155/', '', 'Metoclopramide', 'Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243287, 'Halofantrine', 'Grepafloxacin', 'Major', 'Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses.  QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.  The manufacturer recommends performing an ECG before initiating halofantrine therapy and monitoring cardiac rhythm during and for 8 to 12 hours after completion of therapy.', 'Synergism', 'Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/280156/', '', 'Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin', 'Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243288, 'Isoetharine', 'Halofantrine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/280157/', '', 'Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243289, 'Halofantrine', 'Letermovir', 'Major', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of halofantrine, resulting in an increased risk of QT interval prolongation and ventricular arrhythmias.  The mechanism is inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of halofantrine.', 'DDInter', 'Caution and close monitoring is recommended if halofantrine is prescribed with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors.  The manufacturer recommends performing an ECG before initiating halofantrine therapy and cardiac monitoring during and for 8 to 12 hours after completion of therapy.', 'Metabolism', 'Caution and close monitoring is recommended if halofantrine is prescribed with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/280159/', '', 'Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Proguanil, Sulfadoxine', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243290, 'Halofantrine', 'Levacetylmethadol', 'Major', 'Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses.  QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.  The manufacturer recommends performing an ECG before initiating halofantrine therapy and monitoring cardiac rhythm during and for 8 to 12 hours after completion of therapy.', 'Synergism', 'Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/280161/', '', 'Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine', 'Diamorphine, Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243291, 'Halofantrine', 'Lomefloxacin', 'Major', 'Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses.  QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.  The manufacturer recommends performing an ECG before initiating halofantrine therapy and monitoring cardiac rhythm during and for 8 to 12 hours after completion of therapy.', 'Synergism', 'Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/280162/', '', 'Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine', 'Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, Benzylpenicillin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243292, 'Halofantrine', 'Methotrimeprazine', 'Major', 'Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses.  QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.  The manufacturer recommends performing an ECG before initiating halofantrine therapy and monitoring cardiac rhythm during and for 8 to 12 hours after completion of therapy.', 'Synergism', 'Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/280164/', '', 'Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243293, 'Halofantrine', 'Palbociclib', 'Major', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of halofantrine, resulting in an increased risk of QT interval prolongation and ventricular arrhythmias.  The mechanism is inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of halofantrine.', 'DDInter', 'Caution and close monitoring is recommended if halofantrine is prescribed with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors.  The manufacturer recommends performing an ECG before initiating halofantrine therapy and cardiac monitoring during and for 8 to 12 hours after completion of therapy.', 'Metabolism', 'Caution and close monitoring is recommended if halofantrine is prescribed with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/280167/', '', 'Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Quinine, Primaquine, Proguanil, More', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243294, 'Halofantrine', 'Phenolphthalein', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval.', 'DDInter', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.  The recommended dosage and duration of use should not be exceeded.  Patients treated with lactulose for more than six months should be monitored periodically for electrolyte imbalance.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/280168/', '', 'Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine, Chloroquine', 'Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243295, 'Halofantrine', 'Probucol', 'Major', 'Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses.  QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.  The manufacturer recommends performing an ECG before initiating halofantrine therapy and monitoring cardiac rhythm during and for 8 to 12 hours after completion of therapy.', 'Synergism', 'Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/280171/', '', 'Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine', 'Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Cerivastatin, Lomitapide, Ezetimibe, Niacin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243296, 'Halofantrine', 'Promazine', 'Major', 'Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses.  QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.  The manufacturer recommends performing an ECG before initiating halofantrine therapy and monitoring cardiac rhythm during and for 8 to 12 hours after completion of therapy.', 'Synergism', 'Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/280172/', '', 'Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243297, 'Halofantrine', 'Relugolix', 'Major', 'Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses.  QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.  The manufacturer recommends performing an ECG before initiating halofantrine therapy and monitoring cardiac rhythm during and for 8 to 12 hours after completion of therapy.', 'Synergism', 'Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/280173/', '', 'Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine', 'Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin, Darolutamide, Anastrozole, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243298, 'Halofantrine', 'Ritodrine', 'Major', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.  It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Synergism', 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/280174/', '', 'Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine', 'Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Naproxen, Ibuprofen', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243299, 'Halofantrine', 'Somatrem', 'Moderate', 'Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.  Data from an interaction study performed in growth hormone deficient adults suggest that growth hormone (somatropin) administration can increase the clearance of compounds known to be metabolized by cytochrome P450 isoenzymes, especially CYP450 3A4.', 'DDInter', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/280175/', '', 'Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Primaquine, Proguanil, Sulfadoxine, Chloroquine', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (243300, 'Halofantrine', 'Sulfadoxine', 'Moderate', 'Sulfadoxine-pyrimethamine may increase the extent of halofantrine absorption.', 'DDInter', 'The manufacturer recommends performing an ECG before initiating halofantrine therapy and cardiac monitoring during and for 8 to 12 hours after completion of therapy.', 'Absorption', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/280177/', '', 'Artesunate, Mefloquine, Lumefantrine, Artemether, Tafenoquine, Atovaquone, Hydroxychloroquine, Quinine, Primaquine, Proguanil, Sulfadoxine, Chloroquine', 'Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Proguanil, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, More', 1767369485);
